Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. (Nasdaq: RPTX) is a clinical-stage precision oncology company whose news flow centers on synthetic lethality-based cancer drug development, portfolio monetization, and a planned acquisition by XenoTherapeutics, Inc. Company press releases describe a pipeline that includes RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor, as well as prior development of the PKMYT1 inhibitor lunresertib. News items frequently cover updates on the POLAR and LIONS clinical trials, scientific presentations, and strategic transactions.
Investors and researchers following RPTX news can expect detailed announcements on clinical trial milestones, such as enrollment updates and initial safety, tolerability and early efficacy data from Phase 1 studies. Repare’s disclosures also highlight licensing and collaboration agreements, including an exclusive worldwide license of lunresertib to Debiopharm and an out-licensing of discovery platforms and intellectual property to DCx Biotherapeutics. Additional coverage includes the asset purchase agreement with Gilead Sciences for the Polθ ATPase inhibitor RP-3467 and amendments to collaboration arrangements with partners such as Bristol-Myers Squibb.
A significant portion of recent news focuses on Repare’s strategic review and corporate transactions. The company has announced a definitive arrangement agreement under which XenoTherapeutics, Inc. and Xeno Acquisition Corp. will acquire all of Repare’s common shares through a court-approved plan of arrangement. Related releases describe expected cash consideration per share, the issuance of non-transferable contingent value rights, support and voting agreements with major shareholders, and anticipated delisting from the Nasdaq Global Select Market following closing.
This news page aggregates these company-issued updates, including business highlights, quarterly financial results, conference abstracts and presentations, and regulatory disclosures referenced in Form 8-K filings. Readers interested in RPTX can use this stream to monitor developments in Repare’s precision oncology programs, its partnerships, and the progress of the proposed acquisition and associated contingent value right structure.
Repare Therapeutics Inc. (NASDAQ: RPTX) has announced a proposed underwritten public offering of $75 million in common shares, with a 30-day underwriters' option for an additional $11.25 million. The offering is subject to market conditions, and the exact terms are yet to be finalized. The shares will be sold by Repare, which has previously filed a registration statement with the SEC. Morgan Stanley, Goldman Sachs, Cowen, and Piper Sandler are acting as joint book-running managers for this offering.
Repare Therapeutics, a precision oncology company, announced participation in a fireside chat at H.C. Wainwright's 2nd Annual Precision Oncology Conference on October 20, 2021, at 12:30 p.m. ET. Investors can access a live webcast via their website, with an archived replay available for 90 days. Repare focuses on synthetic lethality for cancer therapies, utilizing their CRISPR-enabled SNIPRx® platform. Their product pipeline includes RP-3500, an ATR inhibitor in Phase 1/2 development, RP-6306, a PKMYT1 inhibitor in Phase 1, and other early-stage programs.
Repare Therapeutics (RPTX) has presented preliminary Phase 1 clinical data for RP-3500 at the AACR-NCI-EORTC conference, indicating positive early efficacy in patients with solid tumors having specific genomic alterations. Out of 101 patients, the drug showed a favorable safety profile, with only 21.8% experiencing grade 3 anemia and no major adverse events leading to discontinuation. The recommended Phase 2 dose was established at 160mg weekly. Promising antitumor activity was noted, with 49% of patients showing clinical benefit, paving the way for further development of RP-3500.
Repare Therapeutics Inc. (NASDAQ: RPTX) announced an inadvertent early issuance of an abstract by the ANE Conference regarding initial clinical data from its Phase 1/2 trial of RP-3500. The presentation, scheduled for October 8, 2021, will feature significantly more patient data than the abstract. Repare will host a virtual investor webcast on the same day to discuss the updated findings. The company specializes in precision oncology using its SNIPRx® platform to develop targeted cancer therapies, including RP-3500 and others currently in development.
Repare Therapeutics Inc. (RPTX) announced key presentations at the AACR-NCI-EORTC Virtual International Conference on October 8, 2021. Initial data from the ongoing Phase 1/2 trial of RP-3500, an ATR inhibitor targeting advanced solid tumors, will be presented. Dr. Timothy Yap will discuss the biomarker-driven trial results during an oral session, while additional preclinical data will be showcased through a poster presentation. A virtual investor webcast is also scheduled for the same day, allowing insights into the promising trial data.
Repare Therapeutics (NASDAQ: RPTX) has appointed Thomas Civik as Chairman of the Board, succeeding Jerel Davis, who remains on the Board. Civik brings over 25 years of experience in the pharma and biotech sectors, including leading roles at Five Prime Therapeutics and Foundation Medicine. His expertise in oncology drug development will be vital as Repare advances its clinical pipeline with candidates RP-3500 and RP-6306. This leadership change is seen as a strategic move to bolster the company's growth and innovation in precision oncology.
Repare Therapeutics Inc. (NASDAQ: RPTX), a clinical-stage precision oncology company, will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on September 9 at 2:45 p.m. ET. The event will highlight the company's proprietary synthetic lethality approach in cancer therapy development, particularly through its SNIPRx® platform. Repare's pipeline includes key products such as RP-3500, an ATR inhibitor in Phase 1/2 trials, and RP-6306, a PKMYT1 inhibitor in Phase 1 trials. A live webcast of the chat will be available on the company's website.
Repare Therapeutics Inc. (RPTX) reported its Q2 financial results, highlighting significant advancements in clinical trials. The company successfully dosed the first patient in the Phase 1b/2 ATTACC trial of its ATR inhibitor RP-3500, aimed at treating molecularly selected cancers. Cash and marketable securities stood at $301 million. However, net losses increased to $26.3 million, or $0.71 per share, compared to $11.8 million, or $2.45 per share, in the same period last year, largely due to rising R&D and G&A expenses.
Repare Therapeutics Inc. (Nasdaq:RPTX), a clinical-stage precision oncology company, announced its senior management's participation in a fireside chat at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference on June 9 at 3:50 p.m. ET. The live webcast can be accessed via the Company’s website, with an archived replay available for 30 days. Repare focuses on synthetic lethality for developing targeted cancer therapies, including its lead candidate RP-3500, an ATR inhibitor in Phase 1/2 development. For more details, visit reparerx.com.
Repare Therapeutics Inc. (RPTX) reported its Q1 2021 financial results, highlighting progress in clinical trials and pipeline advancements. The Company’s ATR inhibitor RP-3500 is in Phase 1/2 development, with initial results expected in H2 2021. The Phase 1 trial of RP-6306 is underway, with the first patient dosed ahead of schedule. As of March 31, 2021, cash equivalents totaled $319.1 million. Net R&D expenses rose to $16.5 million, reflecting increased development costs, while G&A expenses reached $5.2 million. The net loss for the quarter was $21.4 million, or $0.58 per share.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
